← 產業報告目錄

Ligase Enzymes Market by Type (DNA, RNA), Source (Viral, Bacterial, Eukaryotic), Grade (RUO, GMP, Diagnostic), Molecular Biology Workflow (Cloning, Sequencing, Synthetic Biology), Application (Research, Diagnostic, Therapeutic) - Global Forecast 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-09-12頁數 311報告編號 BT9495

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The ligase enzymes market is expected to reach USD 0.36 billion in 2030 from USD 0.26 billion in 2025, at a CAGR of 6.8% during the forecast period. The growth of the ligase enzymes market is driven by the rising adoption of genomics and next-generation sequencing (NGS), the expansion of molecular diagnostics and personalized medicine, and the increasing use of synthetic biology. Ligases play a central role in NGS workflows by enabling adapter ligation & library construction, making them indispensable in large-scale genomics projects and precision medicine initiatives. Its growing application in molecular diagnostics and precision medicine is also expected to fuel the market growth. By grade, the GMP-grade ligase enzymes segment is projected to register the highest CAGR during the forecast period. By grade, the ligase enzymes market is segmented into Research Use Only (RUO), GMP-grade, and diagnostic-grade ligase enzymes. The GMP-grade ligase enzymes segment is expected to grow at the highest CAGR during the forecast period. The growth is supported by the rising demand for GMP-grade ligase enzymes in therapeutic manufacturing, gene therapy, and clinical applications where compliance with stringent quality and safety standards is essential. The increasing investments in cell & gene therapies, biopharmaceutical production, and diagnostic assay development are also expected to fuel the market growth. By source, the viral sources segment accounted for the largest share of the market in 2024. Based on the source, the ligase enzymes market is segmented into viral, bacterial, archaeal, and eukaryotic sources. In 2024, the viral ligases segment accounted for the largest market share owing to its high adoption in applications such as molecular biology workflows, particularly in cloning, DNA repair studies, and next-generation sequencing (NGS) library preparation. Viral ligases, such as T4 DNA ligase, are considered industry standards because of their high efficiency in catalyzing the joining of DNA fragments, making them indispensable in research & industrial biotechnology. By region, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period. By region, the market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period owing to the increasing investments in genomics research, expansion in biotechnology & pharmaceutical industries, and the rising focus on precision medicine. China, Japan, South Korea, and India are significantly scaling up their R&D capabilities through government funding, public–private partnerships, and international collaborations, creating strong demand for molecular biology tools, including ligase enzymes. The growing adoption of next-generation sequencing (NGS), synthetic biology, and molecular diagnostics for cancer, infectious diseases, and rare genetic disorders further supports market expansion. The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24% • By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25% • By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, and the Rest of the World- 15% Promega Corporation (US), New England Biolabs (UK), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), and Takara Bio Inc. (Japan) are some of the key players in the ligase enzymes market. The study includes an in-depth competitive analysis of these key players in the ligase enzymes market and their company profiles, recent developments, and key market strategies. Research Coverage: This research report categorizes the ligase enzymes market by type (DNA, RNA, other ligases), by source (viral, bacterial, archaeal, eukaryotic), by grade (RUO, GMP, diagnostic), by molecular biology workflow (cloning & mutagenesis, synthetic biology, sequencing, nucleic acid amplification), by application (research, diagnostic, therapeutic development & manufacturing, other applications), by end user (academic & research institutes, pharmaceutical and biotechnology companies, hospital & diagnostic laboratories, medical device companies), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report provides in-depth information on significant factors influencing the growth of the ligase enzymes market, including drivers, trends, challenges, and opportunities. A thorough analysis of leading industry players has been undertaken to provide insights into their business profiles, products, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches and acquisitions within the ligase enzyme market. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the ligase enzyme market and its subsegments. It will also help stakeholders better understand the competitive landscape & gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (rising genomics & NGS activities, growth of molecular diagnostics & personalized medicine, and increasing use in synthetic biology), restraints (dependency on research funding), opportunities (development of thermostable/performance-engineered ligases, development of lyophilized/shelf-stable ligases for point-of-care testing and low-resource markets), and challenges (batch-to-batch variability & quality control, growing adoption of ligase independent cloning) influencing the growth of the market. • Product Development/Innovation: Detailed insights on newly launched products of the ligase enzyme market • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ligase enzyme market • Competitive Assessment: In-depth assessment of market share, growth strategies of leading players like New England Biolabs (UK), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), and Promega Corporation (US), among others, in the ligase enzymes market.
目錄 Table of Contents
1 INTRODUCTION 30 1.1 STUDY OBJECTIVES 30 1.2 MARKET DEFINITION 30 1.3 STUDY SCOPE 31 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 31 1.3.2 INCLUSIONS & EXCLUSIONS 32 1.3.3 YEARS CONSIDERED 33 1.3.4 CURRENCY CONSIDERED 33 1.4 STAKEHOLDERS 33 2 RESEARCH METHODOLOGY 34 2.1 RESEARCH DATA 34 2.1.1 SECONDARY DATA 35 2.1.2 PRIMARY DATA 35 2.2 MARKET ESTIMATION METHODOLOGY 37 2.2.1 GLOBAL MARKET SIZE ESTIMATION, 2024 37 2.2.2 SEGMENTAL MARKET ASSESSMENT 40 2.3 MARKET GROWTH RATE PROJECTIONS 42 2.4 DATA TRIANGULATION 44 2.5 RESEARCH ASSUMPTIONS 45 2.6 RESEARCH LIMITATIONS 46 2.7 RISK ASSESSMENT 46 3 EXECUTIVE SUMMARY 47 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS 47 3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS IN LIGASE ENZYMES MARKET 52 3.3 DISRUPTIVE TRENDS SHAPING LIGASE ENZYMES MARKET 53 3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 53 4 PREMIUM INSIGHTS 54 4.1 GLOBAL LIGASE ENZYMES MARKET SNAPSHOT 54 4.2 NORTH AMERICA: LIGASE ENZYMES MARKET, BY TYPE AND COUNTRY (2024) 55 4.3 LIGASE ENZYMES MARKET, BY TYPE (2024) 55 4.4 LIGASE ENZYMES MARKET, BY END USER (2024) 56 4.5 LIGASE ENZYMES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56 4.6 UNMET NEEDS & WHITE SPACES 57 4.7 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES 57 4.7.1 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES 57 4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS 58 4.9 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 59 5 MARKET OVERVIEW 60 5.1 INTRODUCTION 60 5.2 MARKET DYNAMICS 60 5.2.1 DRIVERS 61 5.2.1.1 Rising genomics & NGS activity 61 5.2.1.2 Growth of molecular diagnostics & personalized medicine 62 5.2.1.3 Growing use in synthetic biology 62 5.2.2 RESTRAINTS 63 5.2.2.1 Dependence on research funding 63 5.2.3 OPPORTUNITIES 63 5.2.3.1 Development of thermostable/performance-engineered ligases 63 5.2.3.2 Development of lyophilized/shelf-stable ligases for point-of- care testing (POCT) and low-resource markets 64 5.2.4 CHALLENGES 64 5.2.4.1 Batch-to-batch variability & quality control 64 5.2.4.2 Growth in adoption of sequence and ligase-independent cloning (SLIC) 65 6 INDUSTRY TRENDS 66 6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 66 6.1.1 SHIFT TOWARD HIGH-THROUGHPUT & AUTOMATED WORKFLOWS 66 6.1.2 EXPANSION OF LIGASE APPLICATIONS IN RAPID & POINT-OF-CARE TESTING 66 6.2 VALUE CHAIN ANALYSIS 67 6.3 ECOSYSTEM ANALYSIS 69 6.4 TECHNOLOGY ANALYSIS 70 6.4.1 KEY TECHNOLOGIES 70 6.4.1.1 Precision fermentation 70 6.4.1.2 Enzyme engineering & protein design 71 6.4.2 COMPLEMENTARY TECHNOLOGIES 71 6.4.2.1 Chromatography & purification technologies 71 6.4.2.2 Cryopreservation & stabilization technologies 71 6.5 PATENT ANALYSIS 71 6.5.1 METHODOLOGY 71 6.5.2 PATENTS APPLIED & GRANTED, 2014–2024 72 6.6 TRADE ANALYSIS 74 6.6.1 IMPORT DATA (HS CODE 350790) 74 6.6.2 EXPORT DATA (HS CODE 350790) 76 6.7 PORTER’S FIVE FORCES ANALYSIS 77 6.7.1 THREAT OF NEW ENTRANTS 78 6.7.2 THREAT OF SUBSTITUTES 78 6.7.3 BARGAINING POWER OF SUPPLIERS 78 6.7.4 BARGAINING POWER OF BUYERS 78 6.7.5 INTENSITY OF COMPETITIVE RIVALRY 79 6.8 TARIFF & REGULATORY LANDSCAPE 79 6.8.1 TARIFF DATA (HS CODE 350790) 79 6.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 6.8.3 REGULATORY FRAMEWORK 82 6.9 PRICING ANALYSIS 84 6.9.1 AVERAGE SELLING PRICE TREND OF LIGASE ENZYMES, BY KEY PLAYER, 2022–2024 84 6.9.2 AVERAGE SELLING PRICE OF LIGASE ENZYMES, BY REGION, 2024 85 6.10 KEY CONFERENCES & EVENTS, 2025–2026 86 6.11 KEY STAKEHOLDERS & BUYING CRITERIA 87 6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 87 6.11.2 ROLE OF STAKEHOLDERS IN BUYING PROCESS 88 6.11.3 BUYING CRITERIA 89 6.12 INVESTMENT & FUNDING SCENARIO 90 6.13 IMPACT OF AI/GENERATIVE AI ON LIGASE ENZYMES MARKET 90 6.13.1 AI USE CASES 91 6.13.2 KEY COMPANIES IMPLEMENTING AI 92 6.13.3 FUTURE OF AI 92 6.14 IMPACT OF 2025 US TARIFFS ON LIGASE ENZYMES MARKET 92 6.14.1 INTRODUCTION 92 6.14.2 KEY TARIFF RATES 93 6.14.3 PRICE IMPACT ANALYSIS 93 6.14.4 IMPACT ON COUNTRY/REGION 93 6.14.4.1 US 93 6.14.4.2 Europe 94 6.14.4.3 Asia Pacific 94 6.14.5 END-USE INDUSTRY IMPACT 95 6.14.5.1 Pharmaceutical & biotechnology companies 95 6.14.5.2 Medical device companies 95 6.14.5.3 Academic & research institutes 95 6.14.5.4 Hospitals & diagnostic laboratories 95 7 LIGASE ENZYMES MARKET, BY TYPE 96 7.1 INTRODUCTION 97 7.2 DNA LIGASES 97 7.2.1 HIGH ADOPTION OF DNA LIGASES TO SUPPORT MARKET GROWTH 97 7.3 RNA LIGASES 100 7.3.1 GROWING ADOPTION OF RNA SEQUENCING AND DEVELOPMENT IN RNA THERAPEUTICS TO DRIVE MARKET GROWTH 100 7.4 OTHER LIGASES 103 8 LIGASE ENZYMES MARKET, BY SOURCE 106 8.1 INTRODUCTION 107 8.2 VIRAL LIGASES 107 8.2.1 WIDE COMMERCIAL USE OF VIRAL LIGASES BY COMPANIES TO SUPPORT MARKET GROWTH 107 8.3 BACTERIAL LIGASES 110 8.3.1 HIGH SPECIFICITY AND COMPATIBILITY OF BACTERIAL LIGASES WITH CERTAIN APPLICATIONS TO SUPPORT MARKET GROWTH 110 8.4 EUKARYOTIC LIGASES 113 8.4.1 EXPANDING ROLE OF EUKARYOTIC LIGASES IN DNA REPAIR ASSAYS AND CRISPR-MEDIATED GENOME EDITING TO BOOST MARKET 113 8.5 ARCHAEAL LIGASES 116 8.5.1 RISING DEMAND FOR HIGH-TEMPERATURE LIGATION METHODS IN PCR CLONING TO FUEL GROWTH 116 9 LIGASE ENZYMES MARKET, BY GRADE 119 9.1 INTRODUCTION 120 9.2 RUO-GRADE LIGASES 120 9.2.1 LOW COST OF RUO-GRADE LIGASE ENZYMES TO SUPPORT MARKET GROWTH 120 9.3 GMP-GRADE LIGASES 123 9.3.1 GROWING PIPELINE FOR DNA AND RNA-BASED THERAPEUTICS TO SUPPORT MARKET GROWTH 123 9.4 DIAGNOSTIC-GRADE LIGASES 126 9.4.1 CONTINUOUS PRODUCT INNOVATION TO POSITION DIAGNOSTIC-GRADE LIGASES AS HIGH-OPPORTUNITY GROWTH SEGMENT 126 10 LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW 129 10.1 INTRODUCTION 130 10.2 CLONING & MUTAGENESIS 130 10.2.1 WIDE ADOPTION OF CLONING TECHNIQUES TO SUPPORT MARKET GROWTH 130 10.3 SYNTHETIC BIOLOGY 133 10.3.1 GROWING EXPANSION OF SYNTHETIC BIOLOGY IN HEALTHCARE TO DRIVE MARKET GROWTH 133 10.4 SEQUENCING 136 10.4.1 INCREASING DEMAND FOR LARGE-SCALE GENOME PROJECTS TO BOOST MARKET GROWTH 136 10.5 NUCLEIC ACID AMPLIFICATION 139 10.5.1 GROWING DEMAND FOR RAPID, ACCURATE, AND COST-EFFECTIVE MOLECULAR DIAGNOSTICS TO SUPPORT MARKET GROWTH 139 11 LIGASE ENZYMES MARKET, BY APPLICATION 142 11.1 INTRODUCTION 143 11.2 RESEARCH APPLICATIONS 143 11.2.1 GROWING RESEARCH STUDIES TO SUPPORT MARKET GROWTH 143 11.3 DIAGNOSTIC APPLICATIONS 146 11.3.1 GROWING DEMAND FOR MOLECULAR DIAGNOSTICS AND PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH 146 11.4 THERAPEUTIC DEVELOPMENT & MANUFACTURING 149 11.4.1 GROWING DEMAND FOR GMP-GRADE ENZYMES IN LARGE-SCALE MANUFACTURING TO PROPEL MARKET GROWTH 149 11.5 OTHER APPLICATIONS 152 12 LIGASE ENZYMES MARKET, BY END USER 155 12.1 INTRODUCTION 156 12.2 ACADEMIC & RESEARCH INSTITUTES 156 12.2.1 GROWING RESEARCH STUDIES TO SUPPORT MARKET GROWTH 156 12.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 159 12.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE TO BOOST MARKET GROWTH 159 12.4 HOSPITALS & DIAGNOSTIC LABORATORIES 162 12.4.1 GROWING INTEGRATION OF LIGASE-BASED MOLECULAR DIAGNOSTIC TESTS INTO ROUTINE CARE TO SUPPORT MARKET GROWTH 162 12.5 MEDICAL DEVICE COMPANIES 164 12.5.1 GROWING FOCUS ON RAPID, RELIABLE, AND USER-FRIENDLY DIAGNOSTIC DEVICES TO FUEL GROWTH 164 13 LIGASE ENZYMES MARKET, BY REGION 168 13.1 INTRODUCTION 169 13.2 NORTH AMERICA 169 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 173 13.2.2 US 174 13.2.2.1 Increasing R&D investments and funding to drive market 174 13.2.3 CANADA 176 13.2.3.1 Supportive government policies to propel market growth 176 13.3 EUROPE 179 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 182 13.3.2 GERMANY 183 13.3.2.1 Strong healthcare infrastructure and government-backed genomics initiatives to support market 183 13.3.3 UK 185 13.3.3.1 Growing adoption of genomics and presence of advanced research infrastructure to drive demand 185 13.3.4 FRANCE 188 13.3.4.1 Growing government funding for R&D to propel market 188 13.3.5 ITALY 190 13.3.5.1 Growing research funding to drive market growth 190 13.3.6 SPAIN 193 13.3.6.1 Increasing number of biotechnology companies to drive demand 193 13.3.7 REST OF EUROPE 195 13.4 ASIA PACIFIC 198 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 201 13.4.2 CHINA 202 13.4.2.1 Increasing R&D expenditure to support market growth 202 13.4.3 JAPAN 204 13.4.3.1 Advanced biotechnology industry and strong research base to support market growth 204 13.4.4 INDIA 206 13.4.4.1 Growing government support in evolving biotechnology sector to boost market 206 13.4.5 SOUTH KOREA 209 13.4.5.1 Increasing government support to boost market 209 13.4.6 AUSTRALIA 211 13.4.6.1 Growing biotechnology sector to boost demand 211 13.4.7 REST OF ASIA PACIFIC 213 13.5 LATIN AMERICA 216 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 218 13.5.2 BRAZIL 219 13.5.2.1 Rising focus on biotechnology industry to support market 219 13.5.3 MEXICO 221 13.5.3.1 Government support for biopharmaceutical production to drive market 221 13.5.4 REST OF LATIN AMERICA 224 13.6 MIDDLE EAST 226 13.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST 229 13.6.2 GCC COUNTRIES 229 13.6.2.1 Saudi Arabia 232 13.6.2.1.1 Increasing investments in genomics to drive market 232 13.6.2.2 United Arab Emirates 234 13.6.2.2.1 Advancements in biopharmaceutical sector to drive demand 234 13.6.2.3 Rest of GCC Countries 237 13.6.3 REST OF MIDDLE EAST 239 13.7 AFRICA 241 13.7.1 GROWING FUNDING FOR SUPPORTING RESEARCH INFRASTRUCTURE TO DRIVE MARKET 241 13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 244 14 COMPETITIVE LANDSCAPE 245 14.1 OVERVIEW 245 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2025 245 14.3 REVENUE ANALYSIS, 2020–2024 246 14.4 MARKET SHARE ANALYSIS, 2024 247 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 250 14.5.1 STARS 250 14.5.2 EMERGING LEADERS 250 14.5.3 PERVASIVE PLAYERS 250 14.5.4 PARTICIPANTS 251 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 252 14.5.5.1 Company footprint 252 14.5.5.2 Region footprint 253 14.5.5.3 Type footprint 254 14.5.5.4 Source footprint 254 14.5.5.5 Application footprint 255 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 256 14.6.1 PROGRESSIVE COMPANIES 256 14.6.2 RESPONSIVE COMPANIES 256 14.6.3 DYNAMIC COMPANIES 256 14.6.4 STARTING BLOCKS 256 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 258 14.6.5.1 Detailed list of key startups/SMEs 258 14.6.5.2 Competitive benchmarking of key startups/SMEs 259 14.7 COMPANY VALUATION & FINANCIAL METRICS 260 14.7.1 FINANCIAL METRICS 260 14.7.2 COMPANY VALUATION 260 14.8 BRAND/PRODUCT COMPARISON 261 14.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS 261 14.9 COMPETITIVE SCENARIO 261 14.9.1 DEALS 261 15 COMPANY PROFILES 262 15.1 KEY PLAYERS 262 15.1.1 NEW ENGLAND BIOLABS 262 15.1.1.1 Business overview 262 15.1.1.2 Products offered 262 15.1.1.3 MnM view 263 15.1.1.3.1 Key strengths 263 15.1.1.3.2 Strategic choices 263 15.1.1.3.3 Weaknesses & competitive threats 263 15.1.2 THERMO FISHER SCIENTIFIC INC. 264 15.1.2.1 Business overview 264 15.1.2.2 Products offered 265 15.1.2.3 MnM view 266 15.1.2.3.1 Key strengths 266 15.1.2.3.2 Strategic choices 266 15.1.2.3.3 Weaknesses & competitive threats 266 15.1.3 QIAGEN N.V. 267 15.1.3.1 Business overview 267 15.1.3.2 Products offered 268 15.1.3.3 MnM view 269 15.1.3.3.1 Key strengths 269 15.1.3.3.2 Strategic choices 269 15.1.3.3.3 Weaknesses & competitive threats 269 15.1.4 PROMEGA CORPORATION 270 15.1.4.1 Business overview 270 15.1.4.2 Products offered 270 15.1.4.3 MnM view 271 15.1.4.3.1 Key strengths 271 15.1.4.3.2 Strategic choices 271 15.1.4.3.3 Weaknesses & competitive threats 271 15.1.5 TAKARA BIO INC. 272 15.1.5.1 Business overview 272 15.1.5.2 Products offered 273 15.1.5.3 MnM view 274 15.1.5.3.1 Key strengths 274 15.1.5.3.2 Strategic choices 274 15.1.5.3.3 Weaknesses & competitive threats 274 15.1.6 DANAHER CORPORATION 275 15.1.6.1 Business overview 275 15.1.6.2 Products offered 276 15.1.6.3 MnM view 277 15.1.6.3.1 Key strengths 277 15.1.6.3.2 Strategic choices 277 15.1.6.3.3 Weaknesses & competitive threats 277 15.1.7 AGILENT TECHNOLOGIES, INC. 278 15.1.7.1 Business overview 278 15.1.7.2 Products offered 279 15.1.8 F. HOFFMANN-LA ROCHE LTD. 280 15.1.8.1 Business overview 280 15.1.8.2 Products offered 281 15.1.8.3 Recent developments 282 15.1.8.3.1 Deals 282 15.1.9 MERCK KGAA 283 15.1.9.1 Business overview 283 15.1.9.2 Products offered 284   15.1.10 ARCTICZYMES TECHNOLOGIES 285 15.1.10.1 Business overview 285 15.1.10.2 Products offered 286 15.1.11 BIOSYNTH 287 15.1.11.1 Business overview 287 15.1.11.2 Products offered 287 15.1.12 HIMEDIA LABORATORIES 288 15.1.12.1 Business overview 288 15.1.12.2 Products offered 288 15.1.13 LGC BIOSEARCH TECHNOLOGIES 289 15.1.13.1 Business overview 289 15.1.13.2 Products offered 289 15.1.14 INSPIRALIS LIMITED 290 15.1.14.1 Business overview 290 15.1.14.2 Products offered 290 15.1.15 BIONEER CORPORATION 291 15.1.15.1 Business overview 291 15.1.15.2 Products offered 291 15.2 OTHER PLAYERS 292 15.2.1 GENO TECHNOLOGY INC. 292 15.2.2 MBR, INC. 292 15.2.3 ABCLONAL, INC. 293 15.2.4 NZYTECH 294 15.2.5 JENA BIOSCIENCE GMBH 295 15.2.6 CREATIVE ENZYMES. 295 15.2.7 ENZYNOMICS CO., LTD. 296 15.2.8 BIOCAT GMBH 297 15.2.9 GENAXXON BIOSCIENCE 298 15.2.10 MERIDIAN BIOSICENCE 299 15.2.11 CANVAX 300 15.2.12 BIOTECHRABBIT 301 15.2.13 MCLAB 302 16 APPENDIX 303 16.1 DISCUSSION GUIDE 303 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 307 16.3 CUSTOMIZATION OPTIONS 309 16.4 RELATED REPORTS 309 16.5 AUTHOR DETAILS 310
圖表清單 List of Tables & Figures
TABLE 1 LIGASE ENZYMES MARKET: INCLUSIONS & EXCLUSIONS 32 TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 43 TABLE 3 LIGASE ENZMES MARKET: RISK ASSESSMENT ANALYSIS 46 TABLE 4 LIGASE ENZYMES MARKET: STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES 57 TABLE 5 LIGASE ENZYMES MARKET: EMERGING BUSINESS MODELS & TARGET SEGMENTS 58 TABLE 6 LIGASE ENZYMES MARKET: IMPACT ANALYSIS 61 TABLE 7 LIGASE ENZYMES MARKET: RAW MATERIAL VENDORS 70 TABLE 8 PATENTS APPLIED & GRANTED, 2014–2024 72 TABLE 9 INNOVATIONS & PATENT REGISTRATIONS, 2024 73 TABLE 10 IMPORT VALUE OF HS CODE 350790-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND) 74 TABLE 11 IMPORT VOLUME FOR HS CODE 350790-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (TONS) 75 TABLE 12 EXPORT VALUE OF HS CODE 350790-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND) 76 TABLE 13 EXPORT VOLUME FOR HS CODE 350790-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (TONS) 76 TABLE 14 LIGASE ENZYMES MARKET: PORTER’S FIVE FORCES ANALYSIS 78 TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 TABLE 19 LIGASE ENZYMES MARKET: REGULATORY GUIDELINES 82 TABLE 20 AVERAGE SELLING PRICE TREND OF LIGASE ENZYMES, BY KEY PLAYER, 2022–2024 84 TABLE 21 AVERAGE SELLING PRICE OF LIGASE ENZYMES, BY REGION, 2024 (USD) 85 TABLE 22 LIGASE ENZYMES MARKET: KEY CONFERENCES & EVENTS, 2025–2026 86 TABLE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR LIGASE ENZYMES 88 TABLE 24 BUYING CRITERIA FOR LIGASE ENZYMES, BY END USER 89 TABLE 25 KEY COMPANIES IMPLEMENTING AI IN LIGASE ENZYMES MARKET 92 TABLE 26 LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 97 TABLE 27 DNA LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 98 TABLE 28 NORTH AMERICA: DNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 98 TABLE 29 EUROPE: DNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 98 TABLE 30 ASIA PACIFIC: DNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 99 TABLE 31 LATIN AMERICA: DNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 99 TABLE 32 MIDDLE EAST: DNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 99 TABLE 33 GCC COUNTRIES: DNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 34 RNA LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 101 TABLE 35 NORTH AMERICA: RNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 36 EUROPE: RNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 37 ASIA PACIFIC: RNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 38 LATIN AMERICA: RNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 39 MIDDLE EAST: RNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 40 GCC COUNTRIES: RNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 41 OTHER LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 42 NORTH AMERICA: OTHER LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 43 EUROPE: OTHER LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 44 ASIA PACIFIC: OTHER LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 45 LATIN AMERICA: OTHER LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 46 MIDDLE EAST: OTHER LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 47 GCC COUNTRIES: OTHER LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 48 LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 107 TABLE 49 VIRAL LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 50 NORTH AMERICA: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 51 EUROPE: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 52 ASIA PACIFIC: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 53 LATIN AMERICA: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 54 MIDDLE EAST: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 55 GCC COUNTRIES: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 56 BACTERIAL LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 57 NORTH AMERICA: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 58 EUROPE: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 59 ASIA PACIFIC: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 60 LATIN AMERICA: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 61 MIDDLE EAST: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 62 GCC COUNTRIES: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 63 EUKARYOTIC LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 113 TABLE 64 NORTH AMERICA: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 65 EUROPE: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 66 ASIA PACIFIC: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 67 LATIN AMERICA: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 68 MIDDLE EAST: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 69 GCC COUNTRIES: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 70 ARCHAEAL LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 71 NORTH AMERICA: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 72 EUROPE: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 73 ASIA PACIFIC: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 74 LATIN AMERICA: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 75 MIDDLE EAST: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 76 GCC COUNTRIES: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 77 LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 120 TABLE 78 RUO-GRADE LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 79 NORTH AMERICA: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 80 EUROPE: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 81 ASIA PACIFIC: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 82 LATIN AMERICA: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 83 MIDDLE EAST: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 84 GCC COUNTRIES: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 85 GMP-GRADE LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 86 NORTH AMERICA: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 87 EUROPE: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 88 ASIA PACIFIC: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 89 LATIN AMERICA: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 90 MIDDLE EAST: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 91 GCC COUNTRIES: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 92 DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 93 NORTH AMERICA: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 94 EUROPE: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 95 ASIA PACIFIC: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 96 LATIN AMERICA: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 97 MIDDLE EAST: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 98 GCC COUNTRIES: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 99 LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 130 TABLE 100 LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 101 NORTH AMERICA: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 102 EUROPE: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 103 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 104 LATIN AMERICA: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 105 MIDDLE EAST: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 106 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 107 LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY REGION, 2023–2030 (USD MILLION) 133 TABLE 108 NORTH AMERICA: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 109 EUROPE: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 110 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 111 LATIN AMERICA: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 112 MIDDLE EAST: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 113 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 114 LIGASE ENZYMES MARKET FOR SEQUENCING, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 115 NORTH AMERICA: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 116 EUROPE: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 117 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 118 LATIN AMERICA: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 119 MIDDLE EAST: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 120 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 121 LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 122 NORTH AMERICA: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 123 EUROPE: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 124 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 125 LATIN AMERICA: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 126 MIDDLE EAST: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 127 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 128 LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 143 TABLE 129 LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 130 NORTH AMERICA: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 131 EUROPE: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 132 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 133 LATIN AMERICA: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 134 MIDDLE EAST: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 135 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 136 LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 137 NORTH AMERICA: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 138 EUROPE: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 139 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 140 LATIN AMERICA: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 141 MIDDLE EAST: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 142 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 143 LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 144 NORTH AMERICA: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 145 EUROPE: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 146 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 147 LATIN AMERICA: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 148 MIDDLE EAST: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 149 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 150 LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 151 NORTH AMERICA: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 152 EUROPE: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 153 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 154 LATIN AMERICA: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 155 MIDDLE EAST: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 156 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 157 LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 156 TABLE 158 LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 157 TABLE 159 NORTH AMERICA: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 160 EUROPE: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 161 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 162 LATIN AMERICA: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 163 MIDDLE EAST: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 164 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 165 LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 166 NORTH AMERICA: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 167 EUROPE: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 168 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 169 LATIN AMERICA: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 170 MIDDLE EAST: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 171 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 172 LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 173 NORTH AMERICA: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 174 EUROPE: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 175 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 176 LATIN AMERICA: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 177 MIDDLE EAST: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 178 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 179 LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2023–2030 (USD MILLION) 165 TABLE 180 NORTH AMERICA: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 181 EUROPE: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 182 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 183 LATIN AMERICA: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 184 MIDDLE EAST: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 185 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 186 LIGASE ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 187 NORTH AMERICA: LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 188 NORTH AMERICA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 189 NORTH AMERICA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 171 TABLE 190 NORTH AMERICA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 171 TABLE 191 NORTH AMERICA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 172 TABLE 192 NORTH AMERICA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 172 TABLE 193 NORTH AMERICA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 172 TABLE 194 NORTH AMERICA: MACROECONOMIC INDICATORS 173 TABLE 195 US: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 196 US: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 174 TABLE 197 US: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 175 TABLE 198 US: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 175 TABLE 199 US: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 175 TABLE 200 US: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 176 TABLE 201 CANADA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 177 TABLE 202 CANADA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 177 TABLE 203 CANADA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 177 TABLE 204 CANADA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 178 TABLE 205 CANADA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 178 TABLE 206 CANADA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 178 TABLE 207 EUROPE: LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 208 EUROPE: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 209 EUROPE: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 180 TABLE 210 EUROPE: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 180 TABLE 211 EUROPE: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 181 TABLE 212 EUROPE: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 181 TABLE 213 EUROPE: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 181 TABLE 214 EUROPE: MACROECONOMIC INDICATORS 182 TABLE 215 GERMANY: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 183 TABLE 216 GERMANY: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 183 TABLE 217 GERMANY: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 184 TABLE 218 GERMANY: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 184 TABLE 219 GERMANY: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 184 TABLE 220 GERMANY: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 185 TABLE 221 UK: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 222 UK: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 186 TABLE 223 UK: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 186 TABLE 224 UK: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 187 TABLE 225 UK: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 187 TABLE 226 UK: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 187 TABLE 227 FRANCE: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 228 FRANCE: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 189 TABLE 229 FRANCE: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 189 TABLE 230 FRANCE: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 189 TABLE 231 FRANCE: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 190 TABLE 232 FRANCE: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 190 TABLE 233 ITALY: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 191 TABLE 234 ITALY: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 191 TABLE 235 ITALY: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 192 TABLE 236 ITALY: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 192 TABLE 237 ITALY: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 192 TABLE 238 ITALY: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 193 TABLE 239 SPAIN: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 240 SPAIN: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 194 TABLE 241 SPAIN: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 194 TABLE 242 SPAIN: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 194 TABLE 243 SPAIN: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 195 TABLE 244 SPAIN: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 195 TABLE 245 REST OF EUROPE: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 196 TABLE 246 REST OF EUROPE: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 196 TABLE 247 REST OF EUROPE: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 196 TABLE 248 REST OF EUROPE: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 197 TABLE 249 REST OF EUROPE: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 197 TABLE 250 REST OF EUROPE: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 197 TABLE 251 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 252 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 199 TABLE 253 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 199 TABLE 254 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 200 TABLE 255 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 200 TABLE 256 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 200 TABLE 257 ASIA PACIFIC: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 201 TABLE 258 ASIA PACIFIC: MACROECONOMIC INDICATORS 201 TABLE 259 CHINA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 202 TABLE 260 CHINA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 202 TABLE 261 CHINA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 203 TABLE 262 CHINA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 203 TABLE 263 CHINA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 203 TABLE 264 CHINA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 204 TABLE 265 JAPAN: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 204 TABLE 266 JAPAN: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 205 TABLE 267 JAPAN: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 205 TABLE 268 JAPAN: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 205 TABLE 269 JAPAN: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 206 TABLE 270 JAPAN: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 206 TABLE 271 INDIA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 207 TABLE 272 INDIA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 207 TABLE 273 INDIA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 207 TABLE 274 INDIA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 208 TABLE 275 INDIA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 208 TABLE 276 INDIA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 208 TABLE 277 SOUTH KOREA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 209 TABLE 278 SOUTH KOREA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 209 TABLE 279 SOUTH KOREA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 210 TABLE 280 SOUTH KOREA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 210 TABLE 281 SOUTH KOREA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 210 TABLE 282 SOUTH KOREA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 211 TABLE 283 AUSTRALIA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 284 AUSTRALIA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 212 TABLE 285 AUSTRALIA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 212 TABLE 286 AUSTRALIA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 212 TABLE 287 AUSTRALIA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 213 TABLE 288 AUSTRALIA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 213 TABLE 289 REST OF ASIA PACIFIC: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 290 REST OF ASIA PACIFIC: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 214 TABLE 291 REST OF ASIA PACIFIC: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 214 TABLE 292 REST OF ASIA PACIFIC: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 215 TABLE 293 REST OF ASIA PACIFIC: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 215 TABLE 294 REST OF ASIA PACIFIC: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 215 TABLE 295 LATIN AMERICA: LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 296 LATIN AMERICA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 216 TABLE 297 LATIN AMERICA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 217 TABLE 298 LATIN AMERICA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 217 TABLE 299 LATIN AMERICA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 217 TABLE 300 LATIN AMERICA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 218 TABLE 301 LATIN AMERICA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 218 TABLE 302 LATIN AMERICA: MACROECONOMIC INDICATORS 219 TABLE 303 BRAZIL: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 219 TABLE 304 BRAZIL: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 220 TABLE 305 BRAZIL: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 220 TABLE 306 BRAZIL: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 220 TABLE 307 BRAZIL: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 221 TABLE 308 BRAZIL: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 221 TABLE 309 MEXICO: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 222 TABLE 310 MEXICO: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 222 TABLE 311 MEXICO: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 222 TABLE 312 MEXICO: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 223 TABLE 313 MEXICO: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 223 TABLE 314 MEXICO: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 223 TABLE 315 REST OF LATIN AMERICA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 316 REST OF LATIN AMERICA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 224 TABLE 317 REST OF LATIN AMERICA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 225 TABLE 318 REST OF LATIN AMERICA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 225 TABLE 319 REST OF LATIN AMERICA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 225 TABLE 320 REST OF LATIN AMERICA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 226 TABLE 321 MIDDLE EAST: LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 226 TABLE 322 MIDDLE EAST: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 227 TABLE 323 MIDDLE EAST: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 227 TABLE 324 MIDDLE EAST: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 227 TABLE 325 MIDDLE EAST: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 228 TABLE 326 MIDDLE EAST: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 228 TABLE 327 MIDDLE EAST: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 228 TABLE 328 MIDDLE EAST: MACROECONOMIC INDICATORS 229 TABLE 329 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 230 TABLE 330 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 230 TABLE 331 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 230 TABLE 332 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 231 TABLE 333 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 231 TABLE 334 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 231 TABLE 335 GCC COUNTRIES: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 232 TABLE 336 SAUDI ARABIA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 337 SAUDI ARABIA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 233 TABLE 338 SAUDI ARABIA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 233 TABLE 339 SAUDI ARABIA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 233 TABLE 340 SAUDI ARABIA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 234 TABLE 341 SAUDI ARABIA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 234 TABLE 342 UAE: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 343 UAE: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 235 TABLE 344 UAE: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 235 TABLE 345 UAE: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 236 TABLE 346 UAE: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 236 TABLE 347 UAE: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 236 TABLE 348 REST OF GCC COUNTRIES: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 349 REST OF GCC COUNTRIES: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 237 TABLE 350 REST OF GCC COUNTRIES: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 238 TABLE 351 REST OF GCC COUNTRIES: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 238 TABLE 352 REST OF GCC COUNTRIES: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 238 TABLE 353 REST OF GCC COUNTRIES: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 239 TABLE 354 REST OF MIDDLE EAST: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 355 REST OF MIDDLE EAST: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 240 TABLE 356 REST OF MIDDLE EAST: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 240 TABLE 357 REST OF MIDDLE EAST: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 240 TABLE 358 REST OF MIDDLE EAST: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 241 TABLE 359 REST OF MIDDLE EAST: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 241 TABLE 360 AFRICA: LIGASE ENZYMES MARKET, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 361 AFRICA: LIGASE ENZYMES MARKET, BY GRADE, 2023–2030 (USD MILLION) 242 TABLE 362 AFRICA: LIGASE ENZYMES MARKET, BY SOURCE, 2023–2030 (USD MILLION) 242 TABLE 363 AFRICA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023–2030 (USD MILLION) 243 TABLE 364 AFRICA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 243 TABLE 365 AFRICA: LIGASE ENZYMES MARKET, BY END USER, 2023–2030 (USD MILLION) 243 TABLE 366 MACROECONOMIC OUTLOOK FOR AFRICA 244 TABLE 367 LIGASE ENZYMES MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2021–2025 245 TABLE 368 LIGASE ENZYMES MARKET: DEGREE OF COMPETITION 248 TABLE 369 LIGASE ENZYMES MARKET: REGION FOOTPRINT 253 TABLE 370 LIGASE ENZYMES MARKET: TYPE FOOTPRINT 254 TABLE 371 LIGASE ENZYMES MARKET: SOURCE FOOTPRINT 254 TABLE 372 LIGASE ENZYMES MARKET: APPLICATION FOOTPRINT 255 TABLE 373 LIGASE ENZYMES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 258 TABLE 374 LIGASE ENZYMES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 259 TABLE 375 LIGASE ENZYMES MARKET: DEALS, JANUARY 2021–AUGUST 2025 261 TABLE 376 NEW ENGLAND BIOLABS: COMPANY OVERVIEW 262 TABLE 377 NEW ENGLAND BIOLABS: PRODUCTS OFFERED 262 TABLE 378 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 264 TABLE 379 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 265 TABLE 380 QIAGEN N.V.: COMPANY OVERVIEW 267 TABLE 381 QIAGEN N.V.: PRODUCTS OFFERED 268 TABLE 382 PROMEGA CORPORATION: COMPANY OVERVIEW 270 TABLE 383 PROMEGA CORPORATION: PRODUCTS OFFERED 270 TABLE 384 TAKARA BIO INC.: COMPANY OVERVIEW 272 TABLE 385 TAKARA BIO INC.: PRODUCTS OFFERED 273 TABLE 386 DANAHER CORPORATION: COMPANY OVERVIEW 275 TABLE 387 DANAHER CORPORATION: PRODUCTS OFFERED 276 TABLE 388 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 278 TABLE 389 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 279 TABLE 390 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 280 TABLE 391 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 281 TABLE 392 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–AUGUST 2025 282 TABLE 393 MERCK KGAA: COMPANY OVERVIEW 283 TABLE 394 MERCK KGAA: PRODUCTS OFFERED 284 TABLE 395 ARCTICZYMES TECHNOLOGIES: COMPANY OVERVIEW 285 TABLE 396 ARCTICZYMES TECHNOLOGIES: PRODUCTS OFFERED 286 TABLE 397 BIOSYNTH: COMPANY OVERVIEW 287 TABLE 398 BIOSYNTH: PRODUCTS OFFERED 287 TABLE 399 HIMEDIA LABORATORIES: COMPANY OVERVIEW 288 TABLE 400 HIMEDIA LABORATORIES: PRODUCTS OFFERED 288 TABLE 401 LGC BIOSEARCH TECHNOLOGIES: COMPANY OVERVIEW 289 TABLE 402 LGC BIOSEARCH TECHNOLOGIES: PRODUCTS OFFERED 289 TABLE 403 INSPIRALIS LIMITED: COMPANY OVERVIEW 290 TABLE 404 INSPIRALIS LIMITED: PRODUCTS OFFERED 290 TABLE 405 BIONEER CORPORATION: COMPANY OVERVIEW 291 TABLE 406 BIONEER CORPORATION: PRODUCTS OFFERED 291 TABLE 407 GENO TECHNOLOGY INC.: COMPANY OVERVIEW 292 TABLE 408 MBR, INC.: COMPANY OVERVIEW 292 TABLE 409 ABCLONAL, INC.: COMPANY OVERVIEW 293 TABLE 410 NZYTECH: COMPANY OVERVIEW 294 TABLE 411 JENA BIOSCIENCE GMBH: COMPANY OVERVIEW 295 TABLE 412 CREATIVE ENZYMES: COMPANY OVERVIEW 295 TABLE 413 ENZYNOMICS CO., LTD.: COMPANY OVERVIEW 296 TABLE 414 BIOCAT GMBH: COMPANY OVERVIEW 297 TABLE 415 GENAXXON BIOSCIENCE: COMPANY OVERVIEW 298 TABLE 416 MERIDIAN BIOSCIENCE: COMPANY OVERVIEW 299 TABLE 417 CANVAX: COMPANY OVERVIEW 300 TABLE 418 BIOTECHRABBIT: COMPANY OVERVIEW 301 TABLE 419 MCLAB: COMPANY OVERVIEW 302 FIGURE 1 LIGASE ENZYMES MARKET SEGMENTATION & REGIONAL SCOPE 31 FIGURE 2 RESEARCH DESIGN METHODOLOGY 34 FIGURE 3 LIGASE ENZYMES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 36 FIGURE 4 GLOBAL LIGASE ENZYMES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 37 FIGURE 5 GLOBAL MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2024 38 FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS (2024) 38 FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 40 FIGURE 8 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 40 FIGURE 9 LIGASE ENZYMES MARKET: CAGR PROJECTIONS, 2025−2030 42 FIGURE 10 LIGASE ENZYMES MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS 43 FIGURE 11 DATA TRIANGULATION METHODOLOGY 44 FIGURE 12 LIGASE ENZYMES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 47 FIGURE 13 LIGASE ENZYMES MARKET, BY SOURCE, 2025 VS. 2030 (USD MILLION) 48 FIGURE 14 LIGASE ENZYMES MARKET, BY GRADE, 2025 VS. 2030 (USD MILLION) 48 FIGURE 15 LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2025 VS. 2030 (USD MILLION) 49 FIGURE 16 LIGASE ENZYMES MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 49 FIGURE 17 LIGASE ENZYMES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 50 FIGURE 18 REGIONAL SNAPSHOT OF LIGASE ENZYMES MARKET 51 FIGURE 19 RISING GENOMCS & NGS ACTIVITIES TO PROPEL MARKET GROWTH 54 FIGURE 20 US AND DNA LIGASES COMMANDED LARGER MARKET SHARES IN 2024 55 FIGURE 21 DNA LIGASES ACCOUNTED FOR LARGEST SHARE OF LIGASE ENZYMES MARKET IN 2024 55 FIGURE 22 ACADEMIC & RESEARCH INSTITUTES SEGMENT HELD LARGEST MARKET SHARE IN 2024 56 FIGURE 23 CHINA TO REGISTER HIGHER CAGR DURING FORECAST PERIOD 56 FIGURE 24 LIGASE ENZYMES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60 FIGURE 25 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67 FIGURE 26 LIGASE ENZYMES MARKET: VALUE CHAIN ANALYSIS 68 FIGURE 27 LIGASE ENZYMES MARKET: ECOSYSTEM ANALYSIS 69 FIGURE 28 PATENT APPLICATIONS IN LIGASE ENZYMES MARKET, JANUARY 2014–DECEMBER 2024 72 FIGURE 29 LIGASE ENZYMES MARKET: PORTER’S FIVE FORCES ANALYSIS 77 FIGURE 30 AVERAGE SELLING PRICE TREND OF LIGASE ENZYMES, BY KEY PLAYER, 2022–2024 85 FIGURE 31 AVERAGE SELLING PRICE OF LIGASE ENZYMES, BY REGION, 2024 86 FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LIGASE ENZYMES 87 FIGURE 33 KEY BUYING CRITERIA FOR END USERS 89 FIGURE 34 AI USE CASES 91 FIGURE 35 NORTH AMERICA: LIGASE ENZYMES MARKET SNAPSHOT 170 FIGURE 36 ASIA PACIFIC: LIGASE ENZYMES MARKET SNAPSHOT 198 FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN LIGASE ENZYMES MARKET, 2020–2024 246 FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LIGASE ENZYMES MARKET, 2024 247 FIGURE 39 LIGASE ENZYMES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 251 FIGURE 40 LIGASE ENZYMES MARKET: COMPANY FOOTPRINT 252 FIGURE 41 LIGASE ENZYMES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 257 FIGURE 42 EV/EBITDA OF KEY VENDORS 260 FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 260 FIGURE 44 LIGASE ENZYMES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 261 FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 265 FIGURE 46 QIAGEN N.V.: COMPANY SNAPSHOT (2024) 268 FIGURE 47 TAKARA BIO INC.: COMPANY SNAPSHOT (2024) 273 FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 276 FIGURE 49 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024) 279 FIGURE 50 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 281 FIGURE 51 MERCK KGAA: COMPANY SNAPSHOT (2024) 284 FIGURE 52 ARCTICZYMES TECHNOLOGIES: COMPANY SNAPSHOT (2024) 286

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們